Latest information on COVID-19
Support teaching, research, and patient care.
Dr. Albert Chiou joined Stanford Medicine in September 2017 as a Clinical Assistant Professor of Dermatology. Dr. Chiou earned his Bachelor of Science from Stanford University in 2007 and completed an MPhil in Chemistry, by research, from the University of Cambridge in 2008, where he was a Gates Cambridge Scholar. He received his medical degree from Harvard Medical School, where he also completed a joint business degree. Dr. Chiou performed his dermatology residency at Stanford University and served as Chief Resident in his final year. His clinical focus is general medical dermatology, including atopic dermatitis, acne, psoriasis, skin cancer, and dermatologic surgery. Dr. Chiou is also actively involved in clinical trial research investigating new diagnostic paradigms and treatments for a variety of serious or poorly treated, chronic dermatologic conditions.
I am a clinical researcher interested in evaluating promising new diagnostic paradigms and treatments for serious or poorly treated, chronic skin conditions. My research currently includes:<br/><br/>Therapeutics:<br/><br/>- Treatments for itch from epidermolysis bullosa<br/><br/>- Treatments for chronic wounds for patients with recessive dystrophic epidermolysis bullosa (In collaboration with Dr. Jean Tang and Dr. Peter Marinkovich)<br/><br/>- Treatments for atopic dermatitis, psoriasis, and other inflammatory skin conditions<br/><br/>Diagnostics:<br/><br/>- Artificial intelligence approaches for melanoma and skin cancer early detection<br/><br/>- Imaging mass spectrometry for skin cancer margin analysis and diagnosis<br/><br/>I collaborate with other faculty within the Stanford Skin Innovation and Interventional Research Group (SIIRG) to conduct investigator initiated and sponsored clinical trials seeking to improve care for important dermatologic diseases<br/><br/>Please learn more about our work at: https://siirg.stanford.edu/
SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"
To evaluate the effect of dupilumab on sleep quality in adult patients with moderate to
severe atopic dermatitis (AD)
To evaluate the effect of dupilumab on objective and subjective quantitative sleep
parameters, AD related outcomes, and daytime consequences of sleep deprivation
To continue to assess the safety and tolerability throughout the study
View full details
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
The objective of this study is to assess the efficacy and safety of upadacitinib for the
treatment of adolescent and adult participants with moderate to severe Atopic Dermatitis (AD)
who are candidates for systemic therapy.
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
The objective of this study is to assess the efficacy and safety of upadacitinib combined
with topical corticosteroids (TCS) for the treatment of adolescent and adult participants
with moderate to severe Atopic dermatitis (AD) who are candidates for systemic therapy.
A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa
To determine if Serlopitant (when taken by mouth) is safe and works on itch in patients aged
13 and above with EB.
Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and
safe in treating moderate to severe pruritus in patients with Epidermolysis Bullosa (EB).
Stanford is currently not accepting patients for this trial.
For more information, please contact Claudia Teng, 725-7152.